Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Speaker
Browse by Speaker
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
J
Janda, Claudia
Princess Maxima Center for Pediatric Oncology
Paper 44 - VALIDATION OF A FOCUSED GENE EXPRESSION SIGNATURE TO STRATIFY OSTEOSARCOMA IN AN INDEPENDENT PEDIATRIC AND ADOLESCENT COHORT: A WAY FORWARD FOR FUTURE TRIALS?
Location: The Auditorium, Level 3
Claudia Janda
Favorite
Janeway, Katherine
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Paper 08 - NETWORK-BASED INFERENCE IDENTIFIES PROGNOSTIC SIGNATURES AND DRUGS TARGETING MASTER REGULATORS OF DISTINCT CELL STATES IN OSTEOSARCOMA
Location: The Auditorium, Level 3
Katherine Janeway
Favorite
Paper 18 - PREOPERATIVE RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA TREATED ON AEWS1031: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Location: The Auditorium, Level 3
Katherine Janeway
Favorite
Paper 45 - ANALYSIS OF A LARGE OSTEOSARCOMA SEQUENCING DATASET IDENTIFIES DIFFERENCES IN GENOMICS ACROSS THE AGE SPECTRUM
Location: The Auditorium, Level 3
Katherine Janeway
Favorite
Paper 65 - PRE-TREATMENT CTDNA BURDEN AND GENOMIC FEATURES ARE PROGNOSTIC AMONG PATIENTS WITH METASTATIC EWING SARCOMA TREATED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Location: The Auditorium, Level 3
Katherine Janeway
Favorite
Paper 66 - ARE TREATMENT DELAYS ASSOCIATED WITH A WORSE OUTCOME IN PATIENTS WITH HIGH-GRADE OSTEOSARCOMA? A RETROSPECTIVE ANALYSIS OF DATA FROM THE EURAMOS-1 TRIAL
Location: The Auditorium, Level 3
Katherine Janeway
Favorite
Paper 67 - SIGNIFICANCE OF EARLY LOCAL PROGRESSION IN NEWLY DIAGNOSED HIGH-GRADE OSTEOSARCOMA- A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Location: The Auditorium, Level 3
Katherine Janeway
Favorite
Janeway, Katie
Dana-Farber and Children's Hospital
Herman Suit Lecture: Why I Sequence the Cancer Genome of all Pediatric and AYA Sarcomas
Location: The Auditorium, Level 3
Katie Janeway
Favorite
Jayadeva, Girish
Boehringer Ingelheim Pharmaceuticals Inc.
Paper 23 - A PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MDM2-P53 ANTAGONIST BRIGIMADLIN (BI 907828) IN PATIENTS WITH SOLID TUMORS: SAFETY AND EFFICACY IN PATIENTS WITH LIPOSARCOMA
Location: The Auditorium, Level 3
Girish Jayadeva
Favorite
Jentsch, Christina
National Center for Tumor Diseases (NCT/ UCC), University Hospital Dresden, Technical University Dresden
Paper 17 - THE HEALTH-RELATED QUALITY OF LIFE OF SARCOMA PATIENTS TREATED WITH NEOADJUVANT VERSUS ADJUVANT RADIOTHERAPY - RESULTS OF A MULTI-CENTER OBSERVATIONAL STUDY
Location: The Auditorium, Level 3
Christina Jentsch
Favorite
Jimenez Garcia, Leyre
Nationwide Children's Hospital
Paper 06 - AN OSTEOSARCOMA-INDUCED WOUND HEALING RESPONSE IS ESSENTIAL FOR LUNG COLONIZATION DURING METASTASIS AND IS THERAPEUTICALLY TARGETABLE
Location: The Auditorium, Level 3
Leyre Jimenez Garcia
Favorite
Johnston, Wendy
Department of Surgery, Mount Sinai Hospital, Toronto, ON, Canada
Paper 79 - IMPACT OF CENTER VOLUME ON INDIVIDUAL PROGNOSTICATION OF PATIENTS WITH PRIMARY RETROPERITONEAL SARCOMA: UPDATE OF SARCULATOR NOMOGRAMS
Location: The Auditorium, Level 3
Wendy Johnston
Favorite
Paper 80 - THE PET-RPS STUDY: A PROSPECTIVE EVALUATION OF PET-MR IN PREDICTING RESPONSE TO PREOPERATIVE CHEMOTHERAPY FOR PRIMARY RETROPERITONEAL SARCOMA (RPS)
Location: The Auditorium, Level 3
Wendy Johnston
Favorite
Jonczak, Emily
Sylvester Comprehensive Cancer Center
Paper 03 - RACIAL AND ETHNIC DISPARITIES IN PRESENTATION AND OUTCOMES OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) IN THE ERA OF TARGETED THERAPY
Location: The Auditorium, Level 3
Emily Jonczak
Favorite
Paper 63 - CTDNA-GUIDED SUNITINIB AND REGORAFENIB THERAPY FOR GASTROINTESTINAL STROMAL TUMOR (GIST)
Location: The Auditorium, Level 3
Emily Jonczak
Favorite
Jones, Robin
Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Debate #2: Drugs that have not received regulatory approvals in sarcomas should not be used to treat sarcoma patients except on a clinical trial
Location: The Auditorium, Level 3
Robin Jones
Favorite
Paper 04 - THE PATIENT-REPORTED OUTCOMES (PROS) IN SARCOMA INITIATIVE: TOWARDS A GLOBAL COLLABORATIVE MEASUREMENT STRATEGY
Location: The Auditorium, Level 3
Robin Jones
Favorite
Paper 24 - MILADEMETAN VS. TRABECTEDIN IN PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: RESULTS FROM THE PHASE 3 MANTRA STUDY
Location: The Auditorium, Level 3
Robin Jones
Favorite
Paper 48 - PROTEOMIC FEATURES OF ADOLESCENTS AND YOUNG ADULTS WITH SOFT TISSUE SARCOMAS
Location: The Auditorium, Level 3
Robin Jones
Favorite
Paper 61 - INSIGHT: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR PREVIOUSLY TREATED WITH IMATINIB WITH KIT EXON 11+17/18 MUTATIONS
Location: The Auditorium, Level 3
Robin Jones
Favorite
Paper 62 - PEAK STUDY: A PHASE 3, RANDOMIZED, OPEN-LABEL MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB COMBINATION VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST)
Location: The Auditorium, Level 3
Robin Jones
Favorite
Joshua, Jolissaint
Department of Surgery, Memorial Sloan Kettering, Cancer Center
Paper 78 - A NOVEL SURGICAL COMPLEXITY SCORE TO PREDICT POSTOPERATIVE MORBIDITY FOR PRIMARY RETROPERITONEAL SARCOMA: THE FIRST TARPSWG STUDY FROM THE PROSPECTIVE RESAR REPOSITORY
Location: The Auditorium, Level 3
Jolissaint Joshua
Favorite
Joyce, Ronan
Galway University Hospital, Ireland
Paper 21 - HYPOFRACTIONATED PRE-OPERATIVE RADIOTHERAPY FOR SOFT TISSUE SARCOMA: A SYSTEMATIC REVIEW
Location: The Auditorium, Level 3
Ronan Joyce
Favorite
Jun, John
Department of Medicine, University of California San Diego
Paper 86 - APPLICATION OF SINGLE NUCLEI RNA-SEQUENCING OF HUMAN GASTROINTESTINAL STROMAL TUMORS TO DEFINE TUMOR CELL STATES FOR INFERRING INTRA- AND INTER-TUMORAL HETEROGENEITY FROM BULK TRANSCRIPTOMES
Location: The Auditorium, Level 3
John Jun
Favorite
